William Blair analyst Matt Larew has maintained their bullish stance on MXCT stock, giving a Buy rating today.
Matt Larew has given his Buy rating due to a combination of factors that highlight MaxCyte’s promising financial outlook. The company’s fourth-quarter results slightly surpassed their earlier preannouncement, with total core revenue exceeding expectations. Despite a minor shortfall in adjusted gross margin, the adjusted EBITDA loss was better than anticipated, indicating efficient cost management.
Looking forward, MaxCyte’s guidance for 2025 suggests a solid revenue growth trajectory, with expectations of significant contributions from SeQure Dx. Although the projected organic growth rate is conservative compared to some peers, the company’s strategy appears prudent, with potential for upward revisions throughout the year. Additionally, MaxCyte’s strong cash position and consistent achievement of strategic partnership targets further support the positive outlook, making the Buy rating justified.
In another report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $9.00 price target.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MXCT in relation to earlier this year.